Veracyte
Update in progressVCYT (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Veracyte, Inc. is a diagnostics company that develops genomic tests to inform cancer care. Its offerings include Afirma for thyroid nodules, Decipher Prostate and Decipher Bladder for cancer diagnosis, Prosigna for breast cancer, Percepta for lung cancer, and related nCounter analysis system services. Formerly Calderome, Inc., it was renamed Veracyte in 2008, and was incorporated in 2006. Headquartered in South San Francisco, California.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.34
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!